Microglia are increasingly popular as a therapeutic target for central nervous system (CNS) disorders, including multiple sclerosis and spinal cord injury.
At Aquila, we offer two assays for assessing the ability of your drug candidate to enhance the restorative role of activated microglia, de-risking and furthering you along the best route to clinic.
Working in collaboration with you, we can assess your compound’s ability to dampen the M1 pro-inflammatory response or boost the M2 effector function of activated microglia. Depending on the nature of the compound, we can include a combination of both assessments to investigate the M1 to M2 switch.
Please get in touch for further information.